Bexagliflozin is a sodium-glucose co-transporter 2 inhibitor used to improve glycemic control in patients with type 2 diabetes mellitus. Similar to other SGLT2 inhibitors, bexagliflozin contains three basic moieties: glucose, two benzene rings and a methylene bridge.
- Mechanism
- Curator reviewed · 4 references
Bexagliflozin is a highly selective sodium–glucose co-transporter 2 (SGLT2) inhibitor. SGLT2 is located in the proximal renal tubule, a part of the kidney where most reabsorption takes place, and they transport glucose and sodium from the tubular lumen to the epithelium. By inhibiting SGLT2, bexagliflozin reduces glucose reabsorption in the kidney and promotes its excretion in urine. Therefore, in patients with type 2 diabetes mellitus (T2DM), bexagliflozin reduces blood glucose levels independently of insulin sensitivity.
Aside from improving glycemic control, bexagliflozin may also reduce body weight, systolic blood pressure, and albuminuria. The mechanism of action for these other effects have not been fully elucidated, but it is possible that they depend on the initial natriuresis caused by bexagliflozin, followed by a change in tissue sodium handling.
- Primary indication
- Bexagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.Curator reviewed · 1 structured indication
- Formula / weight
- C24H29ClO7 · 464.94 g/mol (avg)
- First approval
- United States, 2023
- Code names
- EGT0001442 · EGT-1442 · THR-1442
- Brand names
Resolves to
BTCRKOKVYTVOLU-SJSRKZJXSA-NSMILESOC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC=C(Cl)C(CC2=CC=C(OCCOC3CC3)C=C2)=C1What you can answer from here — as of September 13, 2026
Which drugs share a target with Bexagliflozin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account